By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
AdkhabarAdkhabarAdkhabar
Notification Show More
Font ResizerAa
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Reading: Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)
Share
Font ResizerAa
AdkhabarAdkhabar
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Search
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Follow US
Adkhabar > Blog > Health > Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)
Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)
Health

Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)

GlobeNews Wire
Last updated: 22/03/2026 5:38 PM
GlobeNews Wire
Published: 22/03/2026
Share
SHARE

March 20, 2026 16:30 ET  | Source: Zevra Therapeutics

BOSTON, March 20, 2026 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that the Company has granted as of March 18, 2026 an equity inducement award to Justin Renz, the Company’s new Chief Financial Officer pursuant to the Company’s 2023 Employment Inducement Award Plan (as amended and/or restated, the “Inducement Award Plan”). The equity award was approved by the Compensation Committee of the Board of Directors in accordance with Nasdaq Rule 5635(c)(4) and made as a material inducement to Mr. Renz upon acceptance of employment with Zevra.

The Company granted Mr. Renz a new hire option to purchase 300,000 shares of Zevra’s common stock. The option has a 10-year term and an exercise price per share equal to $9.55, which was the closing price of Zevra’s common stock on March 18, 2026. The option vests over four years, subject to Mr. Renz’s continued service through the applicable vesting dates.

About Zevra Therapeutics, Inc.

Zevra Therapeutics, Inc. is a commercial-stage company with a late-stage pipeline committed to redefining what is possible in bringing life-changing therapies to people living with rare diseases. The Company is focused on broadening access through geographic expansion opportunities, progressing its pipeline toward key milestones, and delivering meaningful therapeutics. The commercialization of its lead product, marketed in the U.S. for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a strong corporate foundation and validates its ability to advance therapies from development to market. Zevra’s vision is realized through disciplined execution of its strategic plan and core values — patient centricity, integrity, accountability, innovation, and courage — which guide its efforts to deliver long-term value.

For more information, please visit www.zevra.com or follow us on X and LinkedIn.

Investor Contact

Nichol Ochsner 
+1 (732) 754-2545 
nochsner@zevra.com  

Media Contact

Julie Downs
+1 (508) 246-3230
jdowns@zevra.com

Celebrating 100 years, Duas Rodas unveils its new brand DR Flavors & Ingredients and begins a new cycle of evolution
Lamborghini narrowly misses out on GT World Challenge Europe title in Valencia
Pride of Cows’ New Campaign Encourages Consumers to Ask: “What’s the Source of Your Milk?”
Annature Powers ID Verification and eSigning for OnboardMe
France showcases its Innovation Leadership at the India AI Impact Summit & Expo 2026
TAGGED:5635(c)(4)chieffinancialgrantinducementlistingnasdaqNasdaq:ZVRAnewnewsofficerreportsruletherapeuticsunderUS4884452065zevra
Share This Article
Facebook Email Print
- Advertisement -

Follow US

Find US on Social Medias
FacebookLike
XFollow
YoutubeSubscribe

Weekly Newsletter

Subscribe to our newsletter to get our newest articles instantly!
Popular News

Xinhua Silk Road: Discover China with foreign friends

PRNW Agency
PRNW Agency
30/11/2025
CNRC Reports Q2 2025 Financials Period Ending June 30, 2025; Provides Shareholder Update on Portfolio Companies
Cango Inc. Announces July 2025 Bitcoin Production and Mining Operations Update
Josh Swihart, ECC CEO, Joins Cypherpunk as Strategic Advisor
FOTON Charts a New Course for Global Commercial Vehicles
- Advertisement -
- Advertisement -
- Advertisement -

Categories

  • Automobile
  • Entertainment
  • E-Sports
  • Food
  • Health
  • Technology
  • LifeStyle
  • Travel

About Us

Through our news networks, we raise millions of users' awareness. We are among the world's most reputable news networks.
Quick Link
Top Categories
  • Entertainment

Subscribe US

Subscribe to our newsletter to get our newest articles instantly!

AdkhabarAdkhabar
Copyright © 2021 - 2025 AdKhabar. All Rights Reserved. POWERED BY Life Care News.
Join Us!
Subscribe to our newsletter and never miss our latest news, podcasts etc..
Zero spam, Unsubscribe at any time.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?